Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

IMTX

Immatics N.V

Mar 06 • 04:00PM ET

9.86

-0.29 -2.86 %

Healthcare • Biotechnology • Germany • NASD

Peers: MRNA BNTX ALLO CLLS BLUE ADAP FATE PSTX GOSS TIL

| Held by: KOMP SPDW SBIO ONEQ GWX BBC TMED RFLR KBFR CHNA

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.82	Insider Own	19.63%	Shs Outstand	134.07M	Perf Week	-4.64%
Market Cap	1.32B	Forward P/E	-	EPS next Y	-1.75	Insider Trans	0.00%	Shs Float	107.75M	Perf Month	5.57%
Enterprise Value	789.02M	PEG	-	EPS next Q	-0.45	Inst Own	73.59%	Short Float	5.07%	Perf Quarter	-4.64%
Income	-222.30M	P/S	24.48	EPS this Y	5.06%	Inst Trans	7.99%	Short Ratio	13.42	Perf Half Y	72.38%
Sales	53.99M	P/B	2.33	EPS next Y	1.11%	ROA	-32.19%	Short Interest	5.46M	Perf YTD	-6.10%
Book/sh	4.24	P/C	2.40	EPS next 5Y	0.31%	ROE	-38.20%	52W High	12.41 -20.55%	Perf Year	105.42%
Cash/sh	4.11	P/FCF	-	EPS past 3/5Y	- 18.43%	ROIC	-38.09%	52W Low	3.30 198.79%	Perf 3Y	17.38%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-33.07% 8.86%	Gross Margin	-	Volatility	6.10% 6.45%	Perf 5Y	-4.92%
Dividend TTM	-	EV/Sales	14.61	EPS Y/Y TTM	-2353.85%	Oper. Margin	-392.78%	ATR (14)	0.58	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	11.72	Sales Y/Y TTM	-67.98%	Profit Margin	-411.76%	RSI (14)	48.14	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	11.72	EPS Q/Q	-183.72%	SMA20	-1.89%	Beta	1.35	Target Price	19.48
Payout	0.00%	Debt/Eq	0.03	Sales Q/Q	-61.67%	SMA50	-0.38%	Rel Volume	0.55	Prev Close	10.15
Employees	407	LT Debt/Eq	0.03	Earnings	Mar 05 BMO	SMA200	20.91%	Avg Volume	406.97K	Price	9.86
IPO	Dec 12, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	33.02% 94.84%	Trades		Volume	223,835	Change	-2.86%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-18-25	Initiated	Guggenheim	Buy	$16
May-28-25	Initiated	Deutsche Bank	Buy	$10
Oct-07-24	Initiated	Piper Sandler	Overweight	$19
Nov-02-23	Initiated	Cantor Fitzgerald	Overweight
Mar-31-23	Initiated	Mizuho	Buy	$12
Mar-24-23	Initiated	Bryan Garnier	Buy	$16
Nov-20-20	Initiated	BofA Securities	Buy	$13
Sep-22-20	Initiated	Goldman	Buy	$17
Jul-27-20	Initiated	SVB Leerink	Outperform	$17
Jul-24-20	Initiated	Jefferies	Buy

Mar-05-26 07:30AM	Immatics: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Immatics Announces Full Year 2025 Financial Results and Business Update (GlobeNewswire)
Mar-02-26 05:35PM	Nuvation Bio Inc. (NUVB) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
Feb-25-26 07:25PM	Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
Dec-11-25 07:00AM	Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress (GlobeNewswire)
06:00AM	Loading…
Dec-05-25 06:00AM	Immatics Announces $125 Million Underwritten Offering (GlobeNewswire) -14.24%
Nov-18-25 09:40AM	Company News for Nov 18, 2025 (Zacks) +8.98%
Nov-17-25 08:15AM	Immatics (IMTX) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -7.16%
07:13AM	Immatics: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Immatics Announces Third Quarter 2025 Financial Results and Business Update (GlobeNewswire)
Nov-14-25 09:10AM	CG Oncology, Inc. (CGON) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
Nov-13-25 08:45AM	Xilio Therapeutics, Inc. (XLO) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -6.47%
Nov-12-25 08:30AM	Opus Genetics, Inc. (IRD) Reports Q3 Loss, Beats Revenue Estimates (Zacks) +16.10%
07:00AM	Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Announces Next Development Steps (GlobeNewswire)
Nov-06-25 08:30AM	Monte Rosa Therapeutics (GLUE) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
08:25AM	Loading…
Nov-05-25 08:25AM	Geron (GERN) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
Nov-04-25 08:35AM	Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
Oct-27-25 07:00AM	Immatics Appoints Amie Krause as Chief People Officer (GlobeNewswire)
Oct-20-25 10:30AM	Immatics Highlights Compelling Anti-Tumor Activity of Anzu-cel PRAME Cell Therapy in Metastatic Uveal Melanoma at the ESMO 2025 Presidential Symposium (GlobeNewswire) +11.04%
Oct-01-25 07:00AM	Immatics Appoints Venkat Ramanan as Chief Financial Officer (GlobeNewswire) +5.63%
Aug-18-25 06:12AM	New Strong Sell Stocks for August 15th (Zacks)
Aug-13-25 08:15AM	Immatics (IMTX) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:32AM	Immatics: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Immatics Announces Second Quarter 2025 Financial Results and Business Update (GlobeNewswire)
Aug-11-25 06:55PM	Arcturus Therapeutics (ARCT) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
Aug-07-25 05:10PM	Dynavax Technologies (DVAX) Q2 Earnings and Revenues Beat Estimates (Zacks)
Jul-09-25 10:30AM	Here Is What You Need To Know Before Investing In Immatics N.V. (IMTX) (Insider Monkey)
Jun-03-25 09:55AM	Does Immatics (IMTX) Have the Potential to Rally 174.54% as Wall Street Analysts Expect? (Zacks)
May-31-25 08:00AM	Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma (GlobeNewswire)
May-13-25 07:00AM	Immatics Announces First Quarter 2025 Financial Results and Business Update (GlobeNewswire)
07:35AM	Loading…
May-12-25 07:35AM	ImmunityBio (IBRX) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +7.55%
May-08-25 05:25PM	Cardiff Oncology (CRDF) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
May-06-25 05:25PM	Day One Biopharmaceuticals, Inc. (DAWN) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -10.00%
Apr-23-25 10:00AM	Immatics Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting (GlobeNewswire)
Apr-16-25 10:04AM	Is Immatics (NASDAQ:IMTX) the Best Biotech Penny Stock to Buy According to Hedge Funds? (Insider Monkey) -5.95%
Apr-02-25 03:37PM	Is Immatics (IMTX) the Best German Stock to Buy According to Hedge Funds? (Insider Monkey)
Mar-28-25 01:02PM	Immatics N.V.: Trading Below Cash, But Not Without Reason (Seeking Alpha)
Mar-27-25 07:00AM	Immatics Announces Full Year 2024 Financial Results and Business Update (GlobeNewswire)
Nov-19-24 07:25AM	Immatics Sees Revenue Surge Despite R&D Expenses (TipRanks)
Nov-18-24 07:00AM	Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER IMA402 Targeting PRAME (GlobeNewswire)
Nov-08-24 05:00PM	Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME (GlobeNewswire)
Oct-11-24 06:57AM	Immatics Advances IMA203 to Phase 3 Trial in Melanoma (TipRanks)
Oct-10-24 08:50PM	Immatics Announces Pricing of $150 Million Public Offering (GlobeNewswire) -15.58%
07:30AM	Immatics Announces Proposed $150 Million Public Offering (GlobeNewswire)
06:30AM	Immatics Announces Updated Phase 1b Clinical Data on ACTengine IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial (GlobeNewswire)
Oct-09-24 08:03AM	Immatics N.V. (IMTX) Receives Buy Rating from Analysts (Insider Monkey)
Oct-04-24 09:00AM	Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024 (GlobeNewswire)
Sep-16-24 05:25AM	Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development Update (GlobeNewswire)
Sep-06-24 07:00AM	Immatics Announces Upcoming Oral Presentation at the Society for Melanoma Research Congress 2024 (GlobeNewswire)
Aug-13-24 07:00AM	Immatics Announces Second Quarter 2024 Financial Results and Business Update (GlobeNewswire)
Jul-31-24 07:00AM	Immatics Appoints Alise Reicin to Board of Directors (GlobeNewswire)
Jul-18-24 09:00AM	Immatics Announces Upcoming Oral Presentation at ESMO Congress 2024 (GlobeNewswire)
Jul-08-24 07:00AM	Memo Therapeutics AG appoints Paul Carter as Chairperson (GlobeNewswire)
May-14-24 08:15AM	Immatics (IMTX) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +5.45%
07:00AM	Immatics Announces First Quarter 2024 Financial Results and Business Update (GlobeNewswire)
Mar-21-24 02:52PM	IMTX Stock Earnings: Immatics Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace) -5.89%
07:00AM	Immatics Announces Full Year 2023 Financial Results and Corporate Update (GlobeNewswire)
Mar-13-24 07:07AM	13 Best Biotech Stocks To Buy Under $20 (Insider Monkey)
Jan-17-24 08:30PM	Immatics Announces Pricing of $175 Million Public Offering (GlobeNewswire) -7.36%
04:01PM	Immatics Announces Proposed Public Offering (GlobeNewswire)
Jan-16-24 03:59AM	DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing (PR Newswire)
Nov-30-23 04:00AM	Levicept Appoints Eliot Forster as CEO (GlobeNewswire)
Nov-14-23 07:00AM	Immatics Announces Third Quarter 2023 Financial Results and Business Update (GlobeNewswire)
Nov-08-23 07:00AM	Immatics Reports Interim Clinical Data from ACTengine IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial (GlobeNewswire)
Oct-24-23 07:00AM	Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine IMA203 TCR-T Monotherapy (GlobeNewswire)
Sep-12-23 06:50AM	Protalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of Directors (PR Newswire)
Sep-11-23 07:00AM	Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics (ACCESSWIRE)
Aug-17-23 07:00AM	Immatics Announces Second Quarter 2023 Financial Results and Business Update (GlobeNewswire)
Aug-10-23 07:00AM	Immatics Initiates Phase 1/2 Clinical Trial to Evaluate PRAME TCR Bispecific IMA402 in Patients with Advanced Solid Tumors (GlobeNewswire)
Jul-24-23 07:00AM	Immatics Announces $35 Million Equity Investment from Bristol Myers Squibb (GlobeNewswire)
May-16-23 07:00AM	Immatics Announces First Quarter 2023 Financial Results and Business Update (GlobeNewswire)
May-02-23 07:00AM	Immatics Reports Interim Clinical Data from Ongoing Phase 1b Cohort A Monotherapy with ACTengine® IMA203 TCR-T Targeting PRAME (GlobeNewswire) +27.46%
May-01-23 07:00AM	Immatics Announces First Bristol Myers Squibb Opt-in of TCR-T Candidate from Ongoing Multi-target Strategic Collaboration (GlobeNewswire)
Apr-23-23 08:56AM	TipRanks Perfect 10 List: These 2 Top-Rated Stocks Could Be Long-Term Winners (TipRanks)
Mar-21-23 07:31AM	Immatics Announces Full Year 2022 Financial Results and Corporate Update (GlobeNewswire)
Nov-17-22 07:00AM	Immatics Announces Third Quarter 2022 Financial Results and Business Update (GlobeNewswire)
Oct-10-22 07:37AM	Immatics Announces $110 Million Underwritten Offering of Ordinary Shares (GlobeNewswire) +11.60%
07:36AM	Immatics Reports Interim Clinical Data Update on ACTengine® IMA203 TCR-T Monotherapy Targeting PRAME (GlobeNewswire)
Sep-10-22 03:06AM	Immatics Presents Comprehensive Preclinical Data Set for TCR Bispecific Candidate IMA402 Targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022 (GlobeNewswire)
Aug-23-22 07:00AM	Immatics Announces First Cancer Patient Treated with Second-Generation ACTengine® TCR-T Candidate IMA203CD8 Targeting PRAME (GlobeNewswire)
Aug-09-22 07:00AM	Immatics Announces Second Quarter 2022 Financial Results and Business Update (GlobeNewswire)
Jun-25-22 10:42AM	Do Its Financials Have Any Role To Play In Driving Immatics N.V.'s (NASDAQ:IMTX) Stock Up Recently? (Simply Wall St.)
Jun-07-22 07:00AM	Immatics and Editas Medicine Enter Strategic Research Collaboration and Licensing Agreement to Combine Gamma-Delta T Cell Adoptive Cell Therapies and Gene Editing for the Treatment of Cancer (GlobeNewswire)
Jun-02-22 07:05AM	Immatics Announces First Quarter 2022 Financial Results and Business Update (GlobeNewswire)
06:59AM	Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs (GlobeNewswire)
May-26-22 06:54AM	What Kind Of Shareholders Own Immatics N.V. (NASDAQ:IMTX)? (Simply Wall St.)
May-18-22 07:00AM	Immatics Announces First Patient Treated with ACTengine® IMA203 TCR-T in Combination with Checkpoint Inhibitor Opdivo® (nivolumab) in Patients with Advanced Solid Tumors (GlobeNewswire)
May-10-22 07:00AM	Immatics Initiates Phase 1 Clinical Trial to Evaluate Lead TCR Bispecific IMA401 in Patients with Advanced Solid Tumors (GlobeNewswire)
May-03-22 11:41AM	Immatics (NASDAQ:IMTX) shareholders have endured a 37% loss from investing in the stock a year ago (Simply Wall St.)
Apr-15-22 09:55AM	Wall Street Analysts See a 178% Upside in Immatics (IMTX): Can the Stock Really Move This High? (Zacks)
Mar-31-22 12:13PM	Analysts Are Optimistic We'll See A Profit From Immatics N.V. (NASDAQ:IMTX) (Simply Wall St.)
Mar-23-22 07:00AM	Immatics Announces Full Year 2021 Financial Results and Corporate Update (GlobeNewswire)
Feb-14-22 09:54AM	Here's Why We're Watching Immatics' (NASDAQ:IMTX) Cash Burn Situation (Simply Wall St.)
Dec-16-21 04:42AM	News Flash: Analysts Just Made A Substantial Upgrade To Their Immatics N.V. (NASDAQ:IMTX) Forecasts (Simply Wall St.)
Dec-14-21 06:59AM	Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics TCR Bispecific Program IMA401 (GlobeNewswire) +8.88%
Nov-18-21 08:01AM	Is Immatics N.V. (NASDAQ:IMTX) Popular Amongst Institutions? (Simply Wall St.)
Nov-16-21 07:00AM	Immatics Announces Third Quarter 2021 Financial Results and Provides Business Update (GlobeNewswire)
Nov-09-21 08:00AM	Immatics Reports Clinical Responses across Multiple Solid Tumor Types in Ongoing ACTengine® IMA203 Phase 1a Trial Targeting PRAME (GlobeNewswire) -13.92%
Nov-01-21 08:00AM	Immatics to Present Update on Lead ACTengine® Program IMA203 Targeting PRAME at the Society for Immunotherapy of Cancers 36th Annual Meeting (GlobeNewswire)
02:34AM	Immatics (IMTX) Stock Jumps 5.8%: Will It Continue to Soar? (Zacks)

Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. Its pipeline includes adoptive cell therapy and TCR Bispecifics. The company was founded on March 10, 2020, and is headquartered in Tuebingen, Germany.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IMTX

Immatics N.V

Upgrade your FINVIZ experience